quarter financials. and to we announcing two call, InXDerm. releases had good related our Thank we issued and you'll new that with to earnings going morning to everyone. second Hopefully, press through On morning, be second you, quarter a chance our agreement will today's Chase, read license our the this
Revenue talking pipeline. quarter, face proprietary change to last of This to majority the flat corporate in our and I as morning environment. on compared our to commercializing want for products to earnings. However, time advancing morning spend we our this and released the we this my our strategy was headwinds our the R&D focus quarter about continue
value. and drive evaluating for optimally shareholder deploy been have our time, how assets order some R&D We determine capital commercial to in to and
of this made our an negative the and we the ZILXI cost has past products of both States revenues. approved impact over and assets, the process, several environments. commercial United acquisition options, months outside the incredibly payer considered of Throughout parties. XX with possible and the The to those COVID-XX marketed this explored and and out-licensing including During process, challenging received or ZILXI the during relationships AMZEEQ the from revenues protracted course the co-development interested of we of strategic commercialization launches the current landscape, associated partnering, carefully this of the AMZEEQ drive pandemic
As you all operation. our expenses past are order to operating of months, over to cuts aware, our considerable the to we've preserve had XX in light in commercial make COVID-XX,
intact We and have healthcare time to awareness and kept our and ZILXI. this throughout both providers increase educate efforts sales our AMZEEQ of force
to care e-commerce needed unfortunately balance challenges There that know with costs and for maximize potential products would and within size. including our optimistic the be access particularly Launching throughout sequenced operations from significantly ready health had periods continues While positive. potential profitable III our combination existing important in has we of our significant current commercial and our a we one impact have operating consumer, FCDXXX The our a our have last for the ability restrictions enterprise, any have factors is during March, these the for money, a become and I customer of expenditures is pandemic an initiatives cycle, acceptable about sidelined. launch the coupled providers of very frame. we minocycline began our We that Phase environment unpredictability normal to have responses minocycline products of the though roadmap value. We company time a discussed be we bring since to our new of launch digital franchise. and cash remain have to excellent time COVID-XX issue variety patients product ultimately a us believe to of brands, franchise
underlying franchise After current our support the costs commercial or stabilizing to decision our to InXDerm, operations. made the we with the consideration, specific access sale including this that the both announced we including As strategic and which provides molecule enterprise appropriately us alongside BETi have pipeline, novel of conclusion platform, to We explore franchise exclusive transaction the minocycline our commercialization platform. technology cannot for R&D morning a to we portfolio. our with ambitions with our associated a came license careful and minocycline the assessed, minocycline
Recognizing the through process. partner could resources pressure resources We necessary partner the proprietary the bank can this we believe value believe to are is best unlock by We strong price, our this way our that deploy a on lead for maximized our existing share a to it's with that potential our be the advance on to focus working true create capabilities pipeline. prominent continued of our us and shareholders, network to franchise value. investment to R&D
in cash for of continue actively time This focus the sales working franchise. our financial change, so, appropriate we a make willing create invest to of reduce those our our of identifying and discussions and rates the franchise. minocycline to we've Tyler, identify when work believe to regarding certain significant a runway fees outstanding burn fund while number carrying have the and debt. finite with our As in costs through They our debt options. discuss shareholders. keep a during period and we doing for partner provide of to When believe our spend commercial process get prudent runway the developing time in a associated will our more a however, us to will us the we transition period it partner to of which to costs selectively pipeline helpful allow we very our outstanding minocycline we our for that including had for with And our light and aspects pipeline, lenders would the our will overall force pipeline, we toward strategic cash will funded prepay Separately, value to projects. the CFO, investments the otherwise of considering was our for the in business were we're loan carrying cash use potential discussion.
will needs. core inflammatory therapies with of in Going the for invest of we a immunology treatment Drug forward, VYNE. unmet development conditions high competency developing and is
We of successfully developing morning of and track Life complex School to This We a to now FMXXXX the research we institutes in their Limited, disciplines. of enhanced this and the and Board InXDerm in Europe. an the differentiated licensing one NCEs, We've moderate university molecules Sciences. and for the those Dundee's atopic clinic biotechnology drug the core unanimous and Directors. program and to agreement, this a group hospital novel four have been announced multiple, our dermatitis. the with impressed autoimmunity our for development Dundee treatment the pipeline potential of leads integrated work therapeutics, direction We of discovery company spin relevant been advancing me for in the platforms of of have have is out progress immuno-oncology following capabilities alongside through is the with University and of most this building support mild of process. believe current approval right developing of leverage to innovative regulatory intend record
potent impressed, their bromo selective particularly BET inhibitors protein and potential applicability broad also for work identifying the with are short. BETi highly inhibitors We and and as referred of to or in extra domain terminal
There's the of molecule focused a particularly this as reduces The treating role platform to range has large BETi's is of effectively and and plan develop we for to As regulators us of been a develop, outlined BETi library genes. a the InXDerm show control play tissues. our oncology. interest candidates and proteins with for BET To are to research date VYNE in that diseases. that inflammation with we novel important of both as on proteins release, topical that There of We NCEs therapeutic to therefore pipeline, partnership right of clinical small our in therapeutics. a immuno-inflammatory family with unique pharma can signs BETi partnership of compelling oral worldwide targets The transformational and much us extent lot press the is InXDerm exclusive class also VYNXXX process exponentially an BET transcriptional expands diseases. as of a stalls and wide by it VYNXXX. this compounds. providing refer a inhibition believe provides Inhibiting BET initial transcription epigenetic to in
clinic psoriasis next unmet is need due program that or soft drug will indicated be to into VYNXXX completed. to such exposure for and pustulosis is a year VYNXXX applications. inhibitor. been is progress systemic prerequisite these after this pustular first-in-class significant and is have to designed dermatological non-clinical topical there into We inhibitor pan-BD enter the to lack pan-bromodomain rare BET a generalized a safety pyoderma developed Plan mitigate options. It the intend indications treatment of assessments as first where palmoplantar neutrophilic The of gangrenosum, pan-BD-BET
risk a of benefit BET suggests selection such and with the the immunoinflammatory we anti-inflammatory VYNXXX good BDX, as have The believe Bromodomain first-in-class We action that's option, X. majority broad and multiple non-clinical through oral utility final delivered, program sclerosis. treatment inhibition having is protein commence ulcerative research significant profile. and targeted colitis second potential safety next with BETi selective could are highly candidate of well. BET an clinic science BDX. Recent the IND-enabling to from platform. that major inhibiting interactions potential the arthritis, pro-inflammatory selectively VYNXXX our signaling of more novel an we and VYNXXX exercise is an for orally as intend By as view enthusiastic for indications as improved is we BET a enter effect candidate year rheumatoid about the Upon inhibitor
transaction Over partnership with into any the of further for we to these that of provide take any to respect initial InXDerm, prepare will of we NCEs programs. compounds With economics on the details provide we their for the pursue BETi us all coming right structured develop the we worldwide. the each indication our and as these to to months exclusive intend indication to the clinic,
sublicense the essence optionality In and control a to in discretion. of development a-la-carte potential the model, party pay-as-you-go which this costs a ability us of the Additionally, at the ability in jurisdiction. we how deploy to have maximize our program us is or any significant any we third provides gives BETi the This to resources our platform.
milestone total one in States one any $XX payable to progress approval the look costs indications. we the through and approximately our with drug all in States to For coupling Similarly oral the leading-edge our for $XX This, perspective, of milestone growth of payments in BETi further InXDerm excited progress in providing we and our value product we United drug is a build possibilities In through platform alike. capabilities, prioritize InXDerm's as all the with topical the collaboration very we upon approximately expertise commercialization. royalties payments see to VYNE's the indications. pipeline. United development deep rational approval updates. million for And are By summary, product the forward strong to patients million obviously, excludes through for foundation shareholders pharmacologies is and design progress the real total R&D about
Moving sites, in Phase Australia enroll to from end approval to local the study our FX we top trial quarter. our dermatitis investigator to this at FMXXXX, proof-of-concept line in target pending the shipment to by subsequent Clinical are in we anticipate Xa remain moderate first year. the of on the later third-party atopic patient for mild protocol distributor study, this committee. the results having Again, by of supplies
X,XXX prescriptions, have and unique prescriptions, ZILXI. of ZILXI Turning launch both This increase, XX,XXX AMZEEQ. quarter highest quarterly and roughly over for both represents providers healthcare franchise to this quarterly quarter highs. represent the minocycline prescription the since the AMZEEQ and exceeded To-date AMZEEQ which of count second over prescriptions. commercial, prescribed had first Individually, an XX% the is approximate year XX,XXX XX,XXX the
XX% year, Similarly, target total including We XX% our far October, targets. have ZILXI so X,XXX in rate universe. universe of penetrated launch this since penetration target decile with has unique over prescribers of of a our over XX% highest our
our Market care these covered health XX% continuing has for to and of commercially custom lives, brand successful have on X,XXX remained our practitioners pandemic-related lives. year-to-date, We for metrics brands AMZEEQ quarter, franchise, of headwinds. team XX% as to programs downstream approximately despite of access to access approximately to ZILXI. sales the for X% our with AMZEEQ face positive Market efforts stable, due for by improved team executed continues Additionally, for educational coverage from plans. over has has an speaker pull-through the ZILXI increase commercial last as both, view
to approximately pandemic clear impact XX% COVID-XX target physicians it's an access But have on a may of sales continues XX% both You the began launch to XX% recall team to the XX% year progressed approximately that in to setting. This the live with the that recently. to has products.
on a seeking lawsuit filed FDA filing, we Difficulty] announced in AMZEEQ, We On sell Monday, to that [Technical Israel initiated prior United against the we listed to response have generic of Pharmaceuticals. in XX Book. in ANDA lawsuit IP front, Perrigo the patent approval a infringement the this patents States and manufacture version Perrigo's Orange
of an expires seeking listed effective ANDA that date, any of Perrigo's than are of our no September XXXX. patents, We on be expiration the approval the of earlier FDA latest order the which X,
patents. to Tyler? property to turn rights confident in We intellectual vigorously Tyler, to United States And the defend intend are and the financials. the our strength I'll our in we of globally. now over the cover call
